News

January 2, 2020January 2, 2020

Revlimid-Rituximab Combo Approved in Europe for Previously Treated Follicular Lymphoma

News

The European Commission has approved Bristol-Myers Squibb‘s Revlimid (lenalidomide) in combination with rituximab to treat adults with follicular lymphoma who are no longer responding to other therapies. The combination is the first chemotherapy-free treatment ... Read more

December 17, 2019December 20, 2019

Meeting with FDA Supports Tazemetostat for Some Follicular Lymphoma

News

Epizyme successfully met with the U.S. Food and Drug Administration (FDA) to bolster an upcoming submission of its oral investigational treatment tazemetostat for relapsed or resistant follicular lymphoma, with or ... Read more

December 12, 2019December 12, 2019

Health Canada Approves Adcetris-Chemo Combo for Initial Peripheral T-cell Lymphoma Treatment

News

Health Canada has expanded its approval of Adcetris (brentuximab vedotin) in combination with a chemotherapy regimen for the first-line treatment of peripheral T-cell lymphomas expressing the CD30 marker. The approval is ... Read more

December 9, 2019December 19, 2019

Imbruvica Extends Time to Disease Worsening over Prior Regimen in MCL, Data Shows

News

The time to disease worsening or death usually shortens with each additional line of therapy, but that does not seem to be the case when the Bruton’s tyrosine kinase (BTK) inhibitor ... Read more

December 5, 2019

CHMP Favors Revlimid-Rituximab Combo for Advanced Follicular Lymphoma Patients in EU

News

A branch of the European Medicines Agency voiced support for Revlimid (lenalidomide) in combination with rituximab becoming a treatment option for adults with follicular lymphoma who responded poorly to, or whose disease returned ... Read more

December 5, 2019December 10, 2019

Orencia Given FDA’s Breakthrough Status as Treatment to Prevent Graft-versus-Host Disease After Stem Cell Transplant

News

Bristol-Myers Squibb‘s arthritis medicine Orencia (abatacept) has been named Breakthrough Therapy by the U.S. Food and Drug Administration for the prevention of acute graft-versus-host disease (GvHD) in patients who received ... Read more

November 26, 2019November 26, 2019

FDA Approves Calquence as Treatment Option for Adults with CLL and SLL

News

The U.S. Food and Drug Administration (FDA) has approved AstraZeneca’s Calquence (acalabrutinib) to treat adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The agency’s decision was based ... Read more

November 22, 2019November 22, 2019

EU Advisory Committee Favors Approval of Polivy with MabThera and Bendamustine for Advanced DLBCL

News

An advisory committee for the European Medicines Agency has recommended the conditional approval of Roche‘s Polivy (polatuzumab vedotin) in combination with MabThera (rituximab) and bendamustine (a chemotherapy) for the treatment of ... Read more

November 19, 2019November 19, 2019

FDA Approves BeiGene’s Brukinsa to Treat Adults with Mantle Cell Lymphoma

News

The U.S. Food and Drug Administration (FDA) has granted conditional approval to BeiGene’s Brukinsa (zanubrutinib) as a second-line treatment for adults with mantle cell lymphoma (MCL) who have received at least ... Read more

November 15, 2019

Nanatinostat Combo Put on FDA’s Fast Track for Hard-to-treat Lymphomas Linked to EBV Infection

News

The U.S. Food and Drug Administration has granted fast track designation to a combination of Viracta Therapeutics‘ investigational therapy nanatinostat and the antiviral valganciclovir in treating relapsed or refractory lymphomas ... Read more